Table 3

Summary of the cost and outcome results in base-case analysis
Strategy Cost($) Progression free LYs Overall LYs QALYs Incremental cost per QALY*
1 year (scenario 1)
 Control 2,981.3 0.35 0.51 0.30
 Gefitinib without GPAP 13,775.3 0.56 0.67 0.42 92,968.5
 Gefitinib with GPAP 8,980.4 0.56 0.67 0.42 51,669.9
2 year (scenario 2)
 Control 4,545.6 0.36 0.57 0.33
 Gefitinib without GPAP 22,063.0 0.81 0.97 0.60 65,514.8
 Gefitinib with GPAP 10,660.6 0.81 0.97 0.60 22,870.0
5 year (scenario3)
 Control 4,913.2 0.36 0.57 0.33
 Gefitinib without GPAP 29,705.8 1.06 1.26 0.76 57,788.9
 Gefitinib with GPAP 11,884.7 1.06 1.26 0.76 16,249.9
10 year
 Control 4,917.0 0.36 0.57 0.33
 Gefitinib without GPAP 31,066.9 1.11 1.31 0.79 57,066.4
 Gefitinib with GPAP 12,095.2 1.11 1.31 0.79 15,664.8

* Compared with Control strategy.

Zhu et al.

Zhu et al. BMC Cancer 2013 13:39   doi:10.1186/1471-2407-13-39

Open Data